Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 301–400 of 1,000
Zhang, T., Wang, S., Lin, T.-F., Xie, J., Zhao, L., Liang, Z., Li, Y., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16987 · Cited by 45
“2 Carfilzomib [8] C+R+d/R+d 2(1-3) 87.”
BackgroundInfluentialHari, P., Romanus, D., Palumbo, A. P., Luptakova, K., Rifkin, R. M., Tran, L. M., Raju, A., Farrelly, E., Noga, S. J., Blazer, M. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.012 · Cited by 42
Self-citationThe evolution of stem-cell transplantation in multiple myeloma
Mahajan, S., Tandon, N., & Kumar, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761776 · Cited by 44
Kunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 43
Jagannath, S., Roy, A., Kish, J., Lunacsek, O., Globe, D., Eaddy, M., Kuriakose, E. T., Willey, J., Butler-Bird, S., & Siegel, D. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1195254 · Cited by 41
Self-citationAcute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma
Lum, E. L., Huang, E., Bunnapradist, S., Pham, T. N., & Danovitch, G. M. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.024 · Cited by 41
Park, J. E., Chun, S., Reichel, D., Min, J. S., Lee, S.-C., Han, S., Ryoo, G., Oh, Y., Park, S., Ryu, H.-M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173247 · Cited by 42
Nishida, H., Hayashi, M., Morimoto, C., Sakamoto, M., & Yamada, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0127-y · Cited by 41
Kazandjian, D., Korde, N., Mailankody, S., Hill, E., Figg, W. D., Roschewski, M., & Landgren, O. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5457 · Cited by 38
Fakhri, B., Fiala, M. A., Shah, N. D., Vij, R., & Wildes, T. M. (2019) · Cancer · doi:10.1002/cncr.32601 · Cited by 41
New generation drugs for treatment of multiple myeloma
Alanazi, F. G., Kwa, F. A. A., Burchall, G., & Jackson, D. E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.008 · Cited by 43
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 42
“Lenalidomide is also FDA approved post-ASCT as maintenance therapy as it prolongs both PFS and OS (123); in RRMM setting, it is FDA approved in combination with daratumumab (41), elotuzumab (31), ixazomib (124), and carfilzomib (125).”
BackgroundPromising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Cho, S.-F., Xing, L., Anderson, K. C., & Tai, Y.-T. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 40
Hernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 44
“When lenalidomide was added to Kd (KRd), overall response rate (ORR), PFS and OS improved compared to Rd, although the incidence of grade ≥ 3 adverse events (AEs) was similar [19, 58, 59].”
BackgroundAdvances in the treatment of extramedullary disease in multiple myeloma
Li, Y., Sun, Z., & Qu, X. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101465 · Cited by 42
Cautela, J., Lalevée, N., Ammar, C., Éderhy, S., Peyrol, M., Debourdeau, P., Serin, D., Dolley, Y. L., Michel, N., Orabona, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.046 · Cited by 43
Progress in Myeloma — A Monoclonal Breakthrough
Rajkumar, S. V., & Kyle, R. A. (2016) · New England Journal of Medicine · doi:10.1056/nejme1609835 · Cited by 40
Self-citationAnti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Orlowski, R. Z., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0861 · Cited by 44
“One other toxicity of interest has been cardiac failure, which on the ASPIRE study (20) was seen in 6.”
BackgroundMethodTakamatsu, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6100091 · Cited by 42
Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives
Bohdan, M., Kowalczys, A., Mickiewicz, A., Gruchała, M., & Lewicka, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081647 · Cited by 41
“The literature contains similar reports about bortezomib and ixazomib, which may indicate a class effect [18,35,36].”
BackgroundN-of-1 Policymaking — Tragedy, Trade-offs, and the Demise of Morcellation
Rosenbaum, L. R. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1516161 · Cited by 40
Gupta, N., Goh, Y. T., Min, C., Lee, J. H., Kım, K., Wong, R. S. M., Chim, C. S., Hanley, M. J., Yang, H., Venkatakrishnan, K., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0198-1 · Cited by 40
Management of Carfilzomib-Associated Cardiac Adverse Events
Mikhael, J. R. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.01.008 · Cited by 41
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Perrot, A., Corre, J., & Avet‐Loiseau, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200879 · Cited by 40
Nishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 41
LeBlanc, M. R., Hirschey, R., Bryant, A. L., LeBlanc, T. W., & Smith, S. K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02392-6 · Cited by 40
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
Barankiewicz, J., Salomon‐Perzyński, A., Misiewicz-Krzemińska, I., & Lech‐Marańda, E. (2022) · Cancers · doi:10.3390/cancers14184492 · Cited by 42
“For patients who have not previously been exposed to lenalidomide, RD alone (especially in frail patients) [52], or combined with carfilzomib (the ASPIRE trial) [53,54] ixazomib (the TOURMALINE trial) [55], daratumumab (the POLLUX trial) [56] or elotuzumab (the ELOQUENT-2 trial) [57,58] are highly relevant therapeutic…”
BackgroundMacEwan, J. P., Batt, K., Yin, W., Peneva, D., Sison, S., Vine, S. M., & Chen, C. C. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361035 · Cited by 41
Vesole, D. H., Bilotti, E., Richter, J. R., McNeill, A., McBride, L., Raucci, L., Anand, P., Bednarz, U., Ivanovski, K., Smith, J., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13517 · Cited by 39
“%) relative to the rate reported for the KRd regimen in patients with relapsed or progressive MM (27–37%; Wang et al, 2013; Stewart et al, 2015).”
BackgroundResultSelf-citationThe power of proteasome inhibition in multiple myeloma
Guerrero-Garcia, T. A., Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1543595 · Cited by 38
“8 mos Carfilzomib ASPIRE [94,95] Phase 3 KRd (N = 396) vs.”
BackgroundInfluentialFotiou, D., Ρούσσου, Μ., Gakiopoulou, C., Psimenou, E., Gavriatopoulou, M., Migkou, M., Kanellias, N., Dialoupi, I., Eleutherakis‐Papaiakovou, E., Giannouli, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00381-4 · Cited by 38
Self-citationDavies, F. E., Rifkin, R. M., Costello, C. L., Morgan, G. J., Usmani, S. Z., Abonour, R., Palumbo, A. P., Romanus, D., Hájek, R., Terpos, E., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04534-8 · Cited by 39
“, trial patients were treated in LOTs 2-4), where 47% [4] to 62% [5] of patients had only 1 prior LOT.”
BackgroundSelf-citationTreatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 40
Clinical characteristics of patients with relapsed multiple myeloma
Dimopoulos, M. A., Terpos, E., Niesvizky, R., & Palumbo, A. P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.005 · Cited by 42
“Despite these restrictions, 53% of patients in PX-171-004 and 36% of patients in ASPIRE had PN at baseline [6,21], and 70–83% of patients in the PX-171-004 and PX-171-006 studies had a history of PN [21,22].”
BackgroundMethodResultInfluentialSelf-citationChen, C., Parikh, K., Abouzaid, S., Purnomo, L., McGuiness, C. B., Hussein, M., & Wade, R. L. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.2.236 · Cited by 38
Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 41
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Landgren, O., Lu, S. X., & Hultcrantz, M. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.03.001 · Cited by 40
Berenson, J. R., To, J., Spektor, T. M., Martinez, D., Turner, C., Sánchez, A., Ghermezi, M., Eades, B., Swift, R. A., Schwartz, G. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1899 · Cited by 38
“Together, these preclinical results and this clinical study provide support for further exploring the clinical use of JAK inhibitors in combination with immunomodulatory agents for treating patients with RRMM.”
ResultInfluentialMartínez‐López, J., Wong, S. W. K., Shah, N. D., Bahri, N., Zhou, K., Sheng, Y., Huang, C., Martin, T. G., & Wolf, J. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002037 · Cited by 40
Flyckt, R. L., Coyne, K. D., & Falcone, T. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000275 · Cited by 40
Zhao, Z., Zhao, Z., Lin, Z., Fan, L., Xiahou, Z., Dong, Y., & Weiying, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584350 · Cited by 37
Chari, A., Mezzi, K., Zhu, S., Werther, W., Felici, D., & Lyon, A. R. (2016) · BMC Cancer · doi:10.1186/s12885-016-2955-0 · Cited by 36
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Bobin, A., Liuu, É., Moya, N., Gruchet, C., Sabirou, F., Lévy, A., Gardeney, H., Nsiala, L., Cailly, L., Guidez, S., et al. (2020) · Cancers · doi:10.3390/cancers12102885 · Cited by 38
Chung, R., Tyebally, S. M., Chen, D. H., Kapil, V., Walker, J. M., Addison, D., Ismail-Khan, R. R., Guha, A., & Ghosh, A. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103346 · Cited by 40
Rocchi, S., Tacchetti, P., Pantani, L., Mancuso, K., Rizzello, I., Bezzi, C. D. G., Scalese, M., Dozza, L., Marzocchi, G., Martello, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2820 · Cited by 38
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity
Yang, X., Li, G., Yang, T., Guan, M., An, N., Yang, F., Dai, Q., Zhong, C., Luo, C., Gao, Y., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4894625 · Cited by 37
“These results suggest that immunoproteasomespecific inhibitors with known antitumor activity against MM cells may be beneficial in reducing cardiomyocyte death, compared with the compound carfilzomib [297], which targeted both the b5 standard proteasome and the LMP7 immunoproteasome subunit.”
Self-citationRecent Advances in the Treatment of Patients with Multiple Myeloma
Legarda, M., Cejalvo, M. J., & de la Rubia, J. (2020) · Cancers · doi:10.3390/cancers12123576 · Cited by 39
Jackson, G. H., Pawlyn, C., Cairns, D. A., Tute, R. M. D., Hockaday, A., Collett, C., Jones, J. R., Kishore, B., Garg, M. K., Williams, C. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003454 · Cited by 37
“Carfilzomib has been shown to be safe and effective in relapsed multiple myeloma, both in a doublet combination with dexamethasone (Kd) in the ENDEAVOR trial [4,5] and in triplets such carfilzomib, lenalidomide, and dexamethasone (KRd), evaluated in the ASPIRE trial [6,7].”
Minakata, D., Fujiwara, S., Yokoyama, D., Noguchi, A., Aoe, S., Oyama, T., Koyama, S., Murahashi, R., Nakashima, H., Hyodo, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18654 · Cited by 39
Perel, G., Bliss, J. W., & Thomas, C. M. (2016) · PubMed · Cited by 36
Gavazzoni, M., Vizzardi, E., Gorga, E., Bonadei, I., Rossi, L., Belotti, A., Rossi, G., Ribolla, R., Metra, M., & Raddino, R. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.022 · Cited by 38
Treating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 37
Posttransplant maintenance therapy in multiple myeloma: the changing landscape
Sengsayadeth, S. M., Malard, F., Savani, B. N., Garderet, L., & Mohty, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.23 · Cited by 42
Maiese, E. M., Ainsworth, C., Moine, J.-G. L., Ahdesmäki, O., Bell, J. A., & Hawe, E. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.014 · Cited by 38
New proteasome inhibitors in the treatment of multiple myeloma
Hungria, V., Crusoé, E. D. Q., Bittencourt, R., Maiolino, Â., Magalhães, R., Sobrinho, J. J. N., Pinto, J. V., Fortes, R. C., Moreira, E. D. S., & Tanaka, P. Y. (2018) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.07.003 · Cited by 44
Arterial hypertension in patients under antineoplastic therapy: a systematic review
Katsi, V. K., Magkas, N., Georgiopoulos, G. A., Athanasiadi, E., Virdis, A., Masi, S., Kliridis, P., Hatziyianni, A., Tsioufis, C. P., & Tousoulis, D. M. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002006 · Cited by 41
Proteasome inhibition in multiple myeloma: lessons for other cancers
Saavedra-García, P., Martini, F., & Auner, H. W. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00286.2019 · Cited by 37
Minařík, J., Pika, T., Radocha, J., Jungová, A., Štraub, J., Jelínek, T., Pour, L., Pavlíček, P., Mistrík, M., Brožová, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07732-1 · Cited by 37
Self-citationLim, J. J., Hooi, L., Dan, Y. Y., Bonney, G. K., Zhou, L., Chow, P. K. H., Chee, C. E., Toh, T. B., & Chow, E. K. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02436-9 · Cited by 35
Thrombotic microangiopathy during carfilzomib use: case series in Singapore
Chen, Y., Ooi, M. G. M., Lim, S. F., Lin, A., Lee, J. M., Nagarajan, C., Phipps, C., Lee, Y. S., Grigoropoulos, N. F., Lao, Z., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.62 · Cited by 35
Bashore, C., Jaishankar, P., Skelton, N. J., Fuhrmann, J., Hearn, B. R., Liu, P. S., Renslo, A. R., & Dueber, E. C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00031 · Cited by 34
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 37
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Raza, S., Safyan, R. A., E, E. R. P., Bowman, C. A., & Lentzsch, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680548 · Cited by 40
Richardson, P. G. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., Liedtke, M., Chari, A., Smith, S. D., Lebovic, D. J., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15394 · Cited by 36
Zhang, T., Wang, S., Wan, N., Zhang, L., Zhang, Z., & Jiang, J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.012 · Cited by 34
Wester, R., van der Holt, B., Asselbergs, E., Zweegman, S., Kersten, M. J., Vellenga, E., Kooy, M. V. M., de Weerdt, O., Minnema, M. C., Lonergan, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205476 · Cited by 34
“Thalidomide Normal completion 54 (49) 63 (67) Dose delay, reduction and/or 42 (38) 8 (9) interruption Premature stop 15 (14) 23 (24)”
Self-citationFonseca, R., Arribas, M., Wiedmeier, J. E., Kusne, Y. N., Vélez, M. G., Kosiorek, H., Butterfield, R. J., Kirsch, I. R., Mikhael, J. R., Stewart, A. K., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00794-x · Cited by 35
Self-citationProteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma
Shi, C.-X., Kortüm, K. M., Zhu, Y. X., Jedlowski, P. M., Bruins, L. A., Braggio, E., & Stewart, A. K. (2015) · Haematologica · doi:10.3324/haematol.2015.124297 · Cited by 34
Self-citationJain, T., Sonbol, M. B., Firwana, B., Kolla, K. R., Almader‐Douglas, D., Palmer, J. M., & Fonseca, R. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.021 · Cited by 34
Multiple Myeloma: Current Advances and Future Directions
Martin, T. G., & Huff, C. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.025 · Cited by 36
Peripheral neuropathy in hematologic malignancies – Past, present and future
Li, T., Timmins, H. C., Lazarus, H. M., & Park, S. B. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100653 · Cited by 34
Facon, T. T. F., Niesvizky, R., Mateos, M., Siegel, D. S. D., Rosenbaum, C. A., Bringhen, S., Weisel, K. C., Ho, P. J., Ludwig, H., Kumar, S. K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001965 · Cited by 34
Self-citationPathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 34
Oliva, S., Genuardi, E., París, L., D’Agostino, M., Rogers, J., Rota‐Scalabrini, D., Jacob, A. P., Patriarca, F. F., Luppi, M., Bertazzoni, P., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102016 · Cited by 33
Yousef, S., Kovacsovics-Bankowski, M., Salama, M. E., Bhardwaj, N., Steinbach, M. N., Langemo, A., Kovacsovics, T. J., Marvin, J., Binder, M., Panse, J., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1046658 · Cited by 33
“(12):2077-84; PMID:20308672; http://dx.”
Influentialvan de Donk, N. W. C. J., van der Holt, B., Minnema, M. C., Vellenga, E., Croockewit, S., Kersten, M. J., Borne, P. A. V. D., Ypma, P. F., Schaafsma, R., de Weerdt, O., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30149-2 · Cited by 35
Bringhen, S., D’Agostino, M., Paoli, L. D., Montefusco, V., Liberati, A. M., Galieni, P., Grammatico, S., Muccio, V. E., Esma, F., Angelis, C. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.327 · Cited by 33
Self-citationA question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 34
Self-citationHagen, P. A., & Stiff, P. J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.002 · Cited by 32
Thrombosis in hematological malignancies: mechanisms and implications
Horowitz, N. A., & Brenner, B. (2020) · Thrombosis Research · doi:10.1016/s0049-3848(20)30398-4 · Cited by 32
Wang, L., Li, Q., Yan, H., Jiao, G., Wang, H., Chi, H., Zhou, H., Chen, L., Shan, Y., & Chen, Y. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s266502 · Cited by 34
Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy
Zheng, Y., Huang, S., Xie, B., Zhang, N., Liu, Z., Tse, G., & Liu, T. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101536 · Cited by 36
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 33
“dexa alone for patients with 1–3 prior lines of therapy [14,15].”
BackgroundDiwadkar, S., Patel, A., & Fradley, M. G. (2016) · Case Reports in Cardiology · doi:10.1155/2016/3456287 · Cited by 32
Cavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 33
“7 months and increased the rate of CR or better compared with Rd alone [84].”
ResultPalumbo, A. P., & Sonneveld, P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1053866 · Cited by 31
Self-citationFraz, M. A., Warraich, F. H., Warraich, S. U., Tariq, M. J., Warraich, Z., Khan, A. Y., Usman, M., Ijaz, A., Tenneti, P., Mushtaq, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.011 · Cited by 34
DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
Saitoh, T., & Oda, T. (2021) · Cancers · doi:10.3390/cancers13030504 · Cited by 34
Kastritis, E., Laina, A., Georgiopoulos, G. A., Gavriatopoulou, M., Papanagnou, E., Eleutherakis‐Papaiakovou, E., Fotiou, D., Kanellias, N., Dialoupi, I., Makris, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01141-4 · Cited by 33
Self-citationImpact of carfilzomib-based desensitization on heart transplantation of sensitized candidates
Sriwattanakomen, R., Xu, Q., Demehin, M., Shullo, M. A., Mangiola, M., Hickey, G., Sciortino, C. M., Horn, E. T., Keebler, M., & Zeevi, A. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.03.001 · Cited by 31
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 35
Self-citationBeyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 33
“- Dara-Vd: N=143; - Dara-Rd: N=263 66-70 3 (2-11) Dara SA:”
InfluentialLuo, Q.-W., Lü, Y., Li, L., Yang, Z., Zhao, M., Zheng, Y.-Z., Zhuo, F., Liu, T., Zhang, X., Liu, D., et al. (2022) · Small · doi:10.1002/smll.202205531 · Cited by 32
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 31
Emerging antibodies for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186644 · Cited by 34
“with Rd based on results from the phase III ASPIRE trial.[16] Recently, ixazomib was approved by FDA in combination with Rd for the treatment of MM patients who have received at”
MethodSelf-citationFernando, R. C., Mazzotti, D. R., Azevedo, H., Sandes, A. F., Rizzatti, E. G., de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., de Carvalho, F., Dalboni, M. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38314-8 · Cited by 28
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 33
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
Nishida, H., & Yamada, T. (2019) · Journal of Oncology · doi:10.1155/2019/6084012 · Cited by 32
LeBlanc, R., Bergstrom, D. J., Côté, J. A., Kotb, R. R., Louzada, M., & Sutherland, H. J. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.028 · Cited by 31
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.